• FirefoxInstall the new Firefox »
  •  Dow Down0.44% Nasdaq Down0.42%

    Threshold Pharmaceuticals Inc. (THLD)

    4.06 0.00(0.00%) 4:00PM EDT
    |After Hours : 3.99 Down 0.06 (1.54%) 4:10PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Threshold Pharmaceuticals Inc.
    170 Harbor Way
    Suite 300
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-474-8200
    Fax: 650-474-2529
    Website: http://www.thresholdpharm.com

    Index Membership:N/A
    Full Time Employees:61

    Business Summary 

    Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma and soft tissue sarcoma; Phase I/II clinical trials for multiple myeloma and pancreatic cancer; and Phase I clinical trials for the treatment of solid tumors, pancreatic cancer, and advanced solid tumors. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; and Phase I clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing antiangiogenic therapies in various tumor types in human clinical trials; TH-4000, an investigational hypoxia-activated EGFR tyrosine kinase inhibitor; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license and co-development agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on TH-4000; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Threshold Pharmaceuticals Inc.

    Corporate Governance 
    Threshold Pharmaceuticals Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 9. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 10; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Harold E. Selick Ph.D., 61
    Exec. Chairman and Chief Exec. Officer
    Mr. Joel A. Fernandes , 45
    Principal Financial Officer, Principal Accounting Officer, VP of Fin. and Controller
    Dr. Tillman E. Pearce M.D., 58
    Chief Medical Officer
    Mr. Robert L. Simon , 70
    Sr. VP of Regulatory Affairs & Quality Assurance
    Dr. Nipun Davar Ph.D., MBA, 47
    VP of Pharmaceutical Devel. and Manufacturing
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders